Scholars Central

Research articlePublished 2018

GM-CSF Antibodies and Peripheral Treg Cells as Potential Markers of Disease Activity to Guide Therapeutic Decisions in Pediatric IBD

Authors: Piyali Ray, Fernando Navarro, Yuying Liu, Cynthia S Bell, Lee A Denson, Nicole Fatheree, Thomas Hoang, Marc Rhoads J

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objectives: 1. To measure and compare granulocytemacrophage colony-stimulating factor (GM-CSF) antibodies and peripheral regulatory T cells (Tregs) cells as non-invasive biomarkers in active inflammatory bowel disease (IBD) and remission in pediatric IBD. 2. To determine the ability of these biomarkers to predict severity/type and choice of therapy in pediatric IBD. Methods: We hypothesized that patients with severe IBD requiring biologics will have higher circulating GM-CSF antibodies and lower Foxp3+ Tregs at baseline, with subsequent improvement in response to therapy. 28 patients were prospectively analyzed. Blood collected preand post-treatment was analyzed for GM-CSF antibodies by ELISA and Tregs by flow cytometry. Clinically, PCDAI and PUCAI were scored. Wilcoxon Rank Sum tests were used to compare baseline values between groups, and paired signed-rank tests used to compare pre- and posttreatment values. Results: Median GM-CSF antibodies trended higher (0.50 µg/mL vs. 0.37) and Tregs lower (5.23% vs. 6.71%) in the biologic cohort with no significant difference between cohorts. In response to biologics, 37% showed decrease in GM-CSF antibodies and 75% showed increase in Tregs. GM-CSF antibodies trended higher in Crohn’s disease (CD) than ulcerative colitis (UC) (0.81 vs. 0.31, p=0.073). Activity indices showed significant improvement in the biologic cohort of UC patients (p=0.04). Conclusion: GM-CSF antibodies and peripheral Tregs may reflect disease activity and thereby guide IBD therapy. Although no individual biomarker could predict need for biologics, their trend favors their use in a predictive model to identify the most effective treatment strategy in pediatric IBD.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Gastroenterology and Hepatology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Gastroenterology and Hepatology
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Piyali Ray”
  • BylineArticles whose byline prints “Fernando Navarro”
  • BylineArticles whose byline prints “Yuying Liu”
  • BylineArticles whose byline prints “Cynthia S Bell”
  • BylineArticles whose byline prints “Lee A Denson”
  • BylineArticles whose byline prints “Nicole Fatheree”
  • BylineArticles whose byline prints “Thomas Hoang”
  • BylineArticles whose byline prints “Marc Rhoads J”